Diagnostic considerations of nodules in the cirrhotic liver: A case-based perspective

Pathology Case Reviews

Volumn 14, Issue 1, 2009, Pages 3-12

  Lennerz, Jochen K M ^a   Crippin, Jeffrey S ^a   Brunt, Elizabeth M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dysplastic nodule; Hepatocellular carcinoma; Immunohistochemistry

Indexed keywords

ADULT; BASOPHILIA; CANCER GRADING; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; EOSINOPHILIA; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; STEATOSIS;

EID: 68549096357     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e31819c4238     Document Type: Review

References (115)

1. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005;25:133-142.
2. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology. 1995;22:983-993.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
4. Bruix J, Sherman M. Diagnosis of small HCC. Gastroenterology. 2005;129: 1364.
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepato-cellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
6. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
7. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0 T-MR imaging with pathologic correlation. Invest Radiol. 2008;43:538 -546.
8. Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR. 2006;186:1401-1412.
9. Koda M, Matsunaga Y, Ueki M, et al. Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound: comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound. Eur Radiol. 2004;14: 1100-1108.
10. Stoker J, Romijn MG, de Man RA, et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. Gut. 2002;51:105-107.
11. Hanna RF, Aguirre DA, Kased N, et al. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics. 2008;28:747-769.
12. Takayama T, Makuuchi M, Kojiro M, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15:972-978.
13. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179-S188.
14. Levy I, Greig PD, Gallinger S, et al. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 2001;234:206-209.
15. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology. 1999; 30:889-893.
16. Sakamoto M, Mori T, Masugi Y, et al. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(suppl 1):42-45.
17. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepa-tocellular carcinoma. Hepatology. 2005;42:27-34.
18. Lim JH, Choi D, Cho SK, et al. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology. 2001;220:669-676.
19. Imai Y, Murakami T, Yoshida S, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology. 2000;32:205-212.
20. Asahina Y, Izumi N, Uchihara M, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocel-lular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res. 2003;27:196-204.
21. Gandhi SN, Brown MA, Wong JG, et al. MR contrast agents for liver imaging: what, when, how. Radiographics. 2006;26:1621-1636.
22. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35:25-34.
23. Tanimoto A, Kuwatsuru R, Kadoya M, et al. Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan. J Magn Reson Imaging. 1999;10: 450-460.
24. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology. 1997;205:721-728.
25. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology. 2000;215:727-736.
26. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR. 2000;175:1111-1120.
27. Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology. 1999;30:1174-1178.
28. Bhartia B, Ward J, Guthrie JA, et al. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR. 2003;180:577-584.
29. Choi BI. Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis. J Korean Med Sci. 1998;13:103-116.
30. Kim SR, Ikawa H, Ando K, et al. Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis. World J Gastroenterol. 2007;13:1271- 1274.
31. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepato-carcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol. 1991;22:172-178.
32. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol. 1998;22:656-662.
33. Wu TT, Boitnott J. Dysplastic nodules: a new term for premalignant hepatic nodular lesions. Radiology. 1996;201:21-22.
34. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359: 1995-2004.
35. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94:851-857.
36. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850 -3859.
37. Blum HE. Molecular therapy and prevention of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2003;2:11-22.
38. Riegler JL. Preneoplastic conditions of the liver. Semin Gastrointest Dis. 1996;7:74-87.
39. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687.
40. Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20(suppl 1):S49-S60.
41. Melato M, Laurino L, Mucli E, et al. Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy study. Cancer. 1989; 64:455-459.
42. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis. 2004;24:77-88.
43. Ferrell LD, Crawford JM, Dhillon AP, et al. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol. 1993;17:1113-1123.
44. Quaglia A, Jutand MA, Dhillon A, et al. Classification tool for the systematic histological assessment of hepatocellular carcinoma, macroregenerative nodules, and dysplastic nodules in cirrhotic liver. World J Gastroenterol. 2005;11:6262-6268.
45. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734.
46. Anthony PP. Liver cell dysplasia: a premalignant condition. J Pathol. 1973;109:Pxvii.
47. Anthony PP, Vogel CL, Barker LF. Liver cell dysplasia: a premalignant condition. J Clin Pathol. 1973;26:217-223.
48. Hytiroglou P, Park YN, Krinsky G, et al. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am. 2007;36: 867- 887, vii.
49. Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol. 1998;15:285-299.
50. Wanless IR. Liver biopsy in the diagnosis of hepatocellular carcinoma. Clin Liver Dis. 2005;9:281-285, vii.
51. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology. 1996;23:1112- 1118.
52. Thomas RM, Berman JJ, Yetter RA, et al. Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol. 1992;23: 496-503.
53. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology. 1995;108:812-817.
54. Natarajan S, Theise ND, Thung SN, et al. Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol. 1997;21:312-318.
55. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dyspla-sia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology. 1997;26: 1415-1422.
56. Tiniakos DG, Brunt EM. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver. 1999;19: 58-68.
57. Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology. 2001;39: 66-73.
58. Watanabe S, Okita K, Harada T, et al. Morphologic studies of the liver cell dysplasia. Cancer. 1983;51:2197-2205.
59. Adachi E, Hashimoto H, Tsuneyoshi M. Proliferating cell nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer. 1993;72: 2902-2909.
60. Terada T, Hoso M, Nakanuma Y. Mallory body clustering in adenomatous hyperplasia in human cirrhotic livers: report of four cases. Hum Pathol. 1989;20:868-890.
61. Ueno Y, Moriyama M, Uchida T, et al. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology. 2001;33:357-362.
62. Terada T, Nakanuma Y. Iron-negative foci in siderotic macroregenerative nodules in human cirrhotic liver. A marker of incipient neoplastic lesions. Arch Pathol Lab Med. 1989;113:916-920.
63. Deugnier YM, Charalambous P, Le Quilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 1993;18:1363-1369.
64. Theise ND, Park YN, Kojiro M. Dysplastic nodules and hepatocarcinogen- esis. Clin Liver Dis. 2002;6:497-512.
65. Hytiroglou P, Theise ND, Schwartz M, et al. Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology. 1995;21:703-708.
66. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.
67. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcino-genesis: theoretical and clinical considerations. Semin Liver Dis. 1995; 15:360-371.
68. Theise ND, Fiel IM, Hytiroglou P, et al. Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein. Liver. 1995;15:30 -34.
69. Brunt EM, Walsh SN, Hayashi PH, et al. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Int. 2007;27:662- 671.
70. Menias CO, Surabhi VR, Prasad SR, et al. Mimics of cholangiocarcinoma: spectrum of disease. Radiographics. 2008;28:1115-1129.
71. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocel-lular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.
72. Anatelli F, Chuang ST, Yang XJ, et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008;130:219-223.
73. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441.
74. Abdul-Al HM, Makhlouf HR, Wang G, et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212.
75. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci. 2008;121:3683-3692.
76. Roncalli M, Borzio M, Di Tommaso L. Hepatocellular dysplastic nodules. Ann Ital Chir. 2008;79:81-89.
77. Ikeda K, Kobayashi M, Saitoh S, et al. Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer. J Gastroenterol Hepatol. 2006;21:183-190.
78. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357-363.
79. Hytiroglou P, Kotoula V, Thung SN, et al. Telomerase activity in precan-cerous hepatic nodules. Cancer. 1998;82:1831-1838.
80. Yamamoto T, Uenishi T, Ogawa M, et al. Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg. 2005;22:364-370.
81. Schweizer J, Bowden PE, Coulombe PA, et al. New consensus nomenclature for mammalian keratins. J Cell Biol. 2006;174:169-174.
82. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129:705-733.
83. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34: 427-431.
84. July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002;50:179-188.
85. Kang YK, Hong SW, Lee H, et al. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol. 2004;35:1340-1346.
86. Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene. 2006;25:1242-1250.
87. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30: 1405-1411.
88. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008;9:224.
89. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497-501.
90. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepato-blastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008; 39:224-230.
91. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130: 224-230.
92. Lopez JB. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev. 2005;26:65-79.
93. Haussinger D, Stehle T, Gerok W. Glutamine metabolism in isolated perfused rat liver. The transamination pathway. Biol Chem Hoppe Seyler. 1985;366:527-536.
94. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979;254:2669- 2676.
95. Christa L, Simon MT, Flinois JP, et al. Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology. 1994;106: 1312-1320.
96. Osada T, Sakamoto M, Nagawa H, et al. Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer. 1999; 85:819-831.
97. Bialecki ES, Ezenekwe AM, Brunt EM, et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:361-368.
98. Qayyum A, Graser A, Westphalen A, et al. CT of benign hypervascular liver nodules in autoimmune hepatitis. AJR. 2004;183:1573-1576.
99. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahe-patic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5: 1221-1228.
100. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-125.
101. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40:472-477.
102. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128:620-626.
103. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102:1016-1021.
104. Davila JA, El-Serag HB. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol. 2002;97:3199-3200.
105. Terada T, Nakanuma Y. Utility of pancreatic digestive enzyme immunohis-tochemistry in the differential diagnosis of hepatocellular carcinoma, chol-angiocarcinoma and metastatic adenocarcinoma of the liver. Pathol Int. 1996;46:183-188.
106. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangio- carcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989-997.
107. Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008;26:2800 -2805.
108. Theise ND, Yao JL, Harada K, et al. Hepatic "stem cell" malignancies in adults: four cases. Histopathology. 2003;43:263-271.
109. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298-304.
110. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68:1451-1461.
111. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124:1111-1115.
112. Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl. 2004;10:S3-S8.
113. Park YN, Kojiro M, Di Tommaso L, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dys-plastic nodules. Cancer. 2007;109:915-923.
114. Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl. 2004;10: S9-S15.
115. Roncalli M, Borzio M, Di Tommaso L. Hepatocellular dysplastic nodules. Hepatol Res. 2007;37(suppl 2):S125-S34.